Somewhat Favorable News Coverage Somewhat Unlikely to Impact Aclaris Therapeutics (NASDAQ:ACRS) Share Price
Media stories about Aclaris Therapeutics (NASDAQ:ACRS) have been trending somewhat positive on Saturday, according to Accern. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Aclaris Therapeutics earned a media sentiment score of 0.23 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.5878676445176 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Shares of Aclaris Therapeutics (NASDAQ ACRS) traded down 1.19% during trading on Friday, hitting $24.96. The stock had a trading volume of 264,652 shares. The firm’s market cap is $667.33 million. Aclaris Therapeutics has a 52-week low of $19.75 and a 52-week high of $33.25. The firm’s 50-day moving average is $27.65 and its 200 day moving average is $27.92.
Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.12. On average, analysts expect that Aclaris Therapeutics will post ($3.10) EPS for the current year.
ACRS has been the subject of several research analyst reports. Zacks Investment Research cut Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, May 12th. ValuEngine cut Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, June 6th. Jefferies Group LLC restated a “buy” rating and set a $36.00 price target on shares of Aclaris Therapeutics in a report on Monday, July 31st. Cantor Fitzgerald initiated coverage on Aclaris Therapeutics in a report on Friday, June 16th. They set an “overweight” rating and a $50.00 price target for the company. Finally, BidaskClub cut Aclaris Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. One analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company. Aclaris Therapeutics presently has a consensus rating of “Buy” and an average target price of $39.00.
In related news, Director Andrew N. Schiff purchased 108,601 shares of the company’s stock in a transaction dated Wednesday, August 16th. The stock was acquired at an average cost of $23.02 per share, for a total transaction of $2,499,995.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 16.30% of the stock is owned by corporate insiders.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
Receive News & Stock Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related stocks with our FREE daily email newsletter.